{"id":"cabergoline-dopamine-agonist","safety":{"commonSideEffects":[{"rate":"27–63%","effect":"Nausea"},{"rate":"13–26%","effect":"Headache"},{"rate":"13–17%","effect":"Dizziness"},{"rate":"7–12%","effect":"Fatigue"},{"rate":"5–10%","effect":"Orthostatic hypotension"},{"rate":"5–8%","effect":"Abdominal pain"},{"rate":"<1%","effect":"Valvular heart disease (rare, long-term use)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cabergoline binds to dopamine D2 receptors on lactotroph cells in the pituitary, mimicking dopamine's natural inhibitory effect on prolactin release. This leads to rapid and sustained suppression of elevated prolactin levels. It is highly selective for D2 receptors and has a long half-life, allowing for less frequent dosing compared to other dopamine agonists.","oneSentence":"Cabergoline is a dopamine D2 receptor agonist that inhibits prolactin secretion from the anterior pituitary gland.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:29:31.937Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hyperprolactinemia (prolactin-secreting pituitary adenomas and idiopathic hyperprolactinemia)"},{"name":"Restless legs syndrome"},{"name":"Parkinson's disease (adjunctive therapy)"}]},"trialDetails":[{"nctId":"NCT07492160","phase":"PHASE2","title":"Efficacy of Cabergoline in Inhibiting Lactation and Alleviating Breast Symptoms","status":"RECRUITING","sponsor":"Maimonides Medical Center","startDate":"2026-03-16","conditions":"Pregnancy, Abortion","enrollment":348},{"nctId":"NCT07386080","phase":"PHASE4","title":"Carbergoline for Antipsychotic Induced Hyperprolactinemia.","status":"NOT_YET_RECRUITING","sponsor":"Zealand University Hospital","startDate":"2026-05-01","conditions":"Scizophrenia","enrollment":146},{"nctId":"NCT07072910","phase":"PHASE2","title":"Cabergoline for Episodic Migraine","status":"RECRUITING","sponsor":"Aarhus University Hospital","startDate":"2025-11-12","conditions":"Migraine","enrollment":150},{"nctId":"NCT06029673","phase":"PHASE2","title":"Cabergoline for Lactation Inhibition After Early Second-Trimester Abortion or Pregnancy Loss","status":"COMPLETED","sponsor":"Stanford University","startDate":"2024-02-07","conditions":"Lactation Suppressed","enrollment":69},{"nctId":"NCT07045935","phase":"PHASE4","title":"Metabolic Outcomes in Patients With Prolactinomas Under Dopamine Agonist Treatment","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2025-09-16","conditions":"Prolactinoma","enrollment":60},{"nctId":"NCT02288962","phase":"PHASE3","title":"Dopamine Agonist Treatment of Non-functioning Pituitary Adenomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Olavs Hospital","startDate":"2014-11","conditions":"Pituitary Neoplasms, Adenoma","enrollment":60},{"nctId":"NCT04701333","phase":"PHASE2","title":"Cabergoline for Lactation Inhibition After Second-Trimester Abortion or Loss","status":"COMPLETED","sponsor":"Stanford University","startDate":"2021-04-01","conditions":"Lactation Suppressed","enrollment":73},{"nctId":"NCT04262024","phase":"PHASE1","title":"Clinical Guidance for Proper Treatment of Unexplained Resistant Hyperprolactinemia.","status":"COMPLETED","sponsor":"Woman's Health University Hospital, Egypt","startDate":"2020-02-01","conditions":"Health Education","enrollment":120},{"nctId":"NCT04107480","phase":"PHASE4","title":"PRolaCT - Three Prolactinoma RCTs","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2019-06-21","conditions":"Prolactinoma, Prolactin-Producing Pituitary Tumor","enrollment":880},{"nctId":"NCT02542410","phase":"PHASE2","title":"Dopamine Receptor Agonist Therapy for Pain Relief in Women Suffering From Endometriosis: A Pilot Study","status":"COMPLETED","sponsor":"Boston Children's Hospital","startDate":"2016-05","conditions":"Endometriosis","enrollment":10},{"nctId":"NCT03714763","phase":"NA","title":"Dopamine D2 Receptors(D2R) Imaging in Nonfunctioning Pituitary Adenoma(NFPA)","status":"UNKNOWN","sponsor":"Zhebao Wu","startDate":"2018-11-01","conditions":"Pituitary Adenoma","enrollment":50},{"nctId":"NCT03271918","phase":"PHASE3","title":"Cabergoline in Nonfunctioning Pituitary Adenomas","status":"COMPLETED","sponsor":"University of Sao Paulo General Hospital","startDate":"2015-02-01","conditions":"Pituitary Adenoma, Nonfunctioning Pituitary Adenoma","enrollment":140},{"nctId":"NCT01278342","phase":"PHASE4","title":"Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-09","conditions":"Acromegaly","enrollment":70},{"nctId":"NCT01620138","phase":"PHASE2, PHASE3","title":"Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas","status":"COMPLETED","sponsor":"Universidade Federal do Rio de Janeiro","startDate":"2010-03","conditions":"Non-functioning Pituitary Adenomas, Prolactinomas","enrollment":21},{"nctId":"NCT00605683","phase":"PHASE3","title":"MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist","status":"COMPLETED","sponsor":"Newron Pharmaceuticals SPA","startDate":"2007-11","conditions":"Idiopathic Parkinson's Disease","enrollment":679},{"nctId":"NCT00153972","phase":"PHASE4","title":"Dopamine Turnover Rate as Surrogate Parameter for Diagnosis of Early Parkinson's Disease","status":"COMPLETED","sponsor":"Technische Universität Dresden","startDate":"2005-02","conditions":"Parkinson's Disease","enrollment":39},{"nctId":"NCT01065376","phase":"PHASE4","title":"The Influence of Dopamine Agonist Cabergoline on Oocyte Maturation","status":"COMPLETED","sponsor":"Shin Kong Wu Ho-Su Memorial Hospital","startDate":"2010-01","conditions":"In Vitro Fertilization","enrollment":120},{"nctId":"NCT01052948","phase":"","title":"The Association Between Dopamine Agonists and Cardiac Valvulopathy, Fibrosis and Other Cardiopulmonary Events","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-01","conditions":"Parkinson's Disease, Hyperprolactinemia","enrollment":86939},{"nctId":"NCT01143584","phase":"NA","title":"Efficacy of Rapid Escalation of Cabergoline in Comparison to Conventional Dosing in Prolactin Secreting Macroadenomas.","status":"UNKNOWN","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2010-05","conditions":"Macroprolactinoma","enrollment":20},{"nctId":"NCT01014793","phase":"","title":"Short and Long Term Efficacy of Combined Cabergoline and Octreotide Treatment in Acromegalic Patients","status":"COMPLETED","sponsor":"Federal University of São Paulo","startDate":"2005-05","conditions":"Acromegaly","enrollment":19},{"nctId":"NCT00460616","phase":"","title":"Cardiac Valve Complications in Prolactinomas Treated With Cabergoline","status":"COMPLETED","sponsor":"Federico II University","startDate":"2007-01","conditions":"Prolactinomas","enrollment":50},{"nctId":"NCT00595140","phase":"PHASE4","title":"Acute Application of Pegvisomant and Octreotide in Acromegaly","status":"COMPLETED","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2008-01","conditions":"Acromegaly","enrollment":10},{"nctId":"NCT00440258","phase":"PHASE3","title":"Cabergoline Reduces OHSS","status":"COMPLETED","sponsor":"Instituto Valenciano de Infertilidad, IVI VALENCIA","startDate":"2004-04","conditions":"Ovarian Hyperstimulation Syndrome","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":577,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Cabergoline (Dopamine Agonist)","genericName":"Cabergoline (Dopamine Agonist)","companyName":"University Hospital, Basel, Switzerland","companyId":"university-hospital-basel-switzerland","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cabergoline is a dopamine D2 receptor agonist that inhibits prolactin secretion from the anterior pituitary gland. Used for Hyperprolactinemia (prolactin-secreting pituitary adenomas and idiopathic hyperprolactinemia), Restless legs syndrome, Parkinson's disease (adjunctive therapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}